VALIDOGEN to copresent with Boehringer Ingelheim at BPI West 2019
PRESS RELEASE | VALIDOGEN GmbH
FEBRUARY 27, 2019
Raaba-Grambach, Austria: – Protein expression specialist VALIDOGEN will be a leading contributor to the scientific debate at the upcoming BioProcess International US West Coast (BPI West) meeting in Santa Clara, California.
End-to-end process development
VALIDOGEN, formerly VTU Technology, will be represented by Iskandar Dib, Head of Analytics and DSP who will join Stefan Krahulec, Senior Manager Technology & Innovation at Boehringer Ingelheim RCV to deliver a joint presentation on “Best practice model for collaborative end to end process development and manufacturing using Pichia pastoris“.
Their presentation will form part of BP West’s Pre-Conference Symposium on Microbial Manufacturing on Monday, March 11, (3:30 – 4:00 pm).
Iskandar and Stefan will also participate in the “Thought Leaders Discussion: Where Is, Microbial Production Going?” on March 11, (9:30 – 10:00 am). Topics to be discussed will cover the role of microbial hosts in the bioproduction space, technologies and product advances that will change the market for microbial production and drive industry away from traditional CHO platforms as well as the development of microbial platform approaches.
VALIDOGEN will be present throughout the summit to discuss the advantages of its yield-enhancing “UNLOCK PICHIA protein production toolbox” to enable fine-tuning of protein expression by its diversity of molecular tools and expression strategies for Pichia pastoris.
About VALIDOGEN GmbH
VALIDOGEN GmbH (previously VTU Technology) is a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein expression and production.
VALIDOGEN´s yield-enhancing UNLOCK PICHIA expression platform is based on its proprietary AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening and cultivation regime combined with excellent know-how in fermentation and downstream process development for maximization of product yield and overall process performance. The platform enables highest productivities delivering up to 25 g/L of secreted protein (record productivities of 35 g/L) within a few weeks development time.
VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailor- made solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries.
Headquartered in Grambach, near Graz, Austria, VALIDOGEN is a private company and independent subsidiary of the KonValue Group.
About BioProcess International US West 2019
The BioProcess International US West (BPI West) is one of an international series of BioProcess events that aim to provide leading phase-based bioprocessing knowledge sharing focused on advancing promising biologic developments towards commercial success.
BPI West 2019 is a four-day event opening March 11 at the Santa Clara Convention Center in California.
The meeting will feature e full program of sessions with presentations from leading scientists, engineers and regulators working across the entire bioprocessing spectrum, including Dr. Jerry Murry, Vice President of Amgen, Dr. Rahul Singhvi, Chief Operating Officer of Takeda Vaccines, Inc., Dr. Jens Vogel, President & CEO of Boehringer Ingelheim Fremont Inc. and Dr. Arifa Khan, Supervisory Microbiologist at the US Food & Drug Administration.
The conference is constructed around six scientific tracks covering Viral Safety, Early Stage Process Development, Late Stage PD, Commercial Manufacturing and Single-Use/Flexible Facilities.
The event is organized by KNECT 365 with further information at: https://lifesciences.knect365.com/bpi-west/.
Dr. Thomas Purkarthofer, Head of Business Development, VALIDOGEN GmbH
Tel.: +43 316 4009 4017